What are the characteristics of INVENTIVA stock?

INVENTIVA is a company operating in the Santé · Biotechnologies · Vaccins et laboratoires de recherche sector. The stock is listed on Euronext Paris under ISIN FR0013233012.

What is the recent price evolution of INVENTIVA stock?

Since last close: -4.11 %. Over one week: -23.08 %. Over one year: 21.11 %.

Inventiva Presents Its Strategy at the Biotech Summit 2026

Inventiva announces the participation of its CEO at an investor conference organized by Guggenheim on February 11 and 12, 2026 in New York. This presentation is part of the French biotech's communication with the financial community.

Published on Feb 05, 2026 at 08:32

INVENTIVA

3.50 € -4.11 %

CEO Participation at Guggenheim Conference

Andrew Obenshain, CEO of Inventiva, will participate in a 'fireside chat' during the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 7:00 PM CET (1:00 PM New York time) at the Lotte New York Palace. The company's management will also hold individual meetings with investors during the conference. A webcast of the presentation will be available online.

Focus on Developing Oral Therapies for Metabolic Dysfunction-Associated Steatohepatitis

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

Inventiva specializes in the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company is currently evaluating lanifibranor in a pivotal Phase 3 clinical study for adult patients with this chronic liver disease.

🏢 Other stocks — Santé

🗞️ Ipsen's Stock Rebounds Over 2%, Marking One of the Top Gains in SBF 120 🗞️ Valneva's Shares Continue to Fall, Threatening Key Support at €2.26 🗞️ DBV Technologies Shares Drop Nearly 4% Breaking Below 200-Day Moving Average 🗞️ Sanofi Shares Lead the CAC 40, Surpassing €78

Context

Period

Period: 1T2026

Key reported figures

Revenue: 0€

Risks mentioned

Aucune garantie que les bons de souscription seront exercés en totalité.
Inventiva a un historique d'exploitation limité et a subi des pertes importantes.

Opportunities identified

Estime que sa trésorerie lui permettra de financer ses activités jusqu'à la mi-premier trimestre 2027.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

CEO Participation at Guggenheim Conference

Focus on Developing Oral Therapies for Metabolic Dysfunction-Associated Steatohepatitis

Context

Also read